Literature DB >> 23196427

Photodynamic therapy in combination with talaporfin sodium induces mitochondrial apoptotic cell death accompanied with necrosis in glioma cells.

Yuichi Miki1, Jiro Akimoto, Sakino Yokoyama, Tomomi Homma, Masateru Tsutsumi, Jo Haraoka, Kazuya Hirano, Masatoshi Beppu.   

Abstract

Photodynamic therapy (PDT) induces selective cell death of neoplastic tissue and connecting vasculature by combining photosensitizers with light. Here we clarified the types of cell death induced by PDT in combination with the photosensitizer talaporfin sodium (mono-L-aspartyl chlorine e6, NPe6) in order to evaluate the potential of this therapy as a treatment for glioma. PDT with NPe6 (NPe6-PDT) induces dose-dependent cell death in human glioblastoma T98G cells. Specifically, cell death modalities were observed in NPe6-PDT treated T98G cells, including signs of apoptosis (activation of caspase-3, expression of phosphatidylserine, and DNA fragmentation) and necrosis (stainability of propidium iodide). In addition, high doses of NPe6-PDT decreased the proportion of apoptotic cell death, while increasing necrosis. Closer examination of apoptotic characteristics revealed release of cytochrome-c from mitochondria as well as activation of both caspse-9 and caspase-3 in cells treated with low doses of NPe6-PDT. Benziloxycarbonyl-Leu-Gln(OMe)-His-Asp(OMe)-fluoromethyl-ketone (Z-LEHD-fmk), a caspase-9 specific inhibitor, and benziloxycarbonyl-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethyl-ketone (Z-DQMD-fmk), a caspase-3 specific inhibitor, showed dose-dependent prevention of cell death in NPe6-PDT treated cells, indicating that mitochondrial apoptotic pathway was a factor in the observed cell death. Further, the cell morphology was observed after PDT. Time- and NPe6-dose dependent necrotic features were increased in NPe6-PDT treated cells. These results suggest that NPe6-PDT could be an effective treatment for glioma if used in mild doses to avoid the increased necrosis that may induce undesirable obstacles.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23196427     DOI: 10.1248/bpb.b12-00567

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  8 in total

1.  Photodynamic therapy using talaporfin sodium induces concentration-dependent programmed necroptosis in human glioblastoma T98G cells.

Authors:  Yuichi Miki; Jiro Akimoto; Keiko Moritake; Chihiro Hironaka; Yasuyuki Fujiwara
Journal:  Lasers Med Sci       Date:  2015-06-25       Impact factor: 3.161

2.  Photodynamic anti-cancer effects of fullerene [C₆₀]-PEG complex on fibrosarcomas preferentially over normal fibroblasts in terms of fullerene uptake and cytotoxicity.

Authors:  Ryoko Asada; Feng Liao; Yasukazu Saitoh; Nobuhiko Miwa
Journal:  Mol Cell Biochem       Date:  2014-02-05       Impact factor: 3.396

3.  Photodynamic therapy by lysosomal-targeted drug delivery using talaporfin sodium incorporated into inactivated virus particles.

Authors:  Sharmin Akter; Mizuho Inai; Sachiko Saito; Norihiro Honda; Hisanao Hazama; Tomoyuki Nishikawa; Yasufumi Kaneda; Kunio Awazu
Journal:  Laser Ther       Date:  2019-12-31

4.  P38/MAPK contributes to endothelial barrier dysfunction via MAP4 phosphorylation-dependent microtubule disassembly in inflammation-induced acute lung injury.

Authors:  Lingfei Li; Jiongyu Hu; Ting He; Qiong Zhang; Xu Yang; Xiaodong Lan; Dongxia Zhang; Hao Mei; Bing Chen; Yuesheng Huang
Journal:  Sci Rep       Date:  2015-03-09       Impact factor: 4.379

5.  Fluorescence characteristics and lifetime images of photosensitizers of talaporfin sodium and sodium pheophorbide a in normal and cancer cells.

Authors:  Kamlesh Awasthi; Kazuhito Yamamoto; Kazunari Furuya; Takakazu Nakabayashi; Liming Li; Nobuhiro Ohta
Journal:  Sensors (Basel)       Date:  2015-05-18       Impact factor: 3.576

6.  Preclinical validation of talaporfin sodium-mediated photodynamic therapy for esophageal squamous cell carcinoma.

Authors:  Shinya Ohashi; Osamu Kikuchi; Mihoko Tsurumaki; Yukie Nakai; Hiroi Kasai; Takahiro Horimatsu; Shin'ichi Miyamoto; Akira Shimizu; Tsutomu Chiba; Manabu Muto
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

Review 7.  Photodynamic Therapy for Malignant Brain Tumors.

Authors:  Jiro Akimoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-02-16       Impact factor: 1.742

8.  Intraoperative Photodynamic Diagnosis Using Talaporfin Sodium Simultaneously Applied for Photodynamic Therapy against Malignant Glioma: A Prospective Clinical Study.

Authors:  Kazuhide Shimizu; Masayuki Nitta; Takashi Komori; Takashi Maruyama; Takayuki Yasuda; Yu Fujii; Ken Masamune; Takakazu Kawamata; Taketoshi Maehara; Yoshihiro Muragaki
Journal:  Front Neurol       Date:  2018-01-30       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.